MEDICAL SERVICES

EDUCATION

Medical School

  • Yale University School of Medicine , 1992 , New Haven , CT

Internship

Pediatrics
  • Boston Children's Hospital , 1993 , Boston , MA

Residency

Pediatrics
  • Boston Combined Residency Program (BCRP) , 1995 , Boston , MA

Fellowship

Pediatric Hematology-Oncology
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center , 1997 , Boston , MA

CERTIFICATIONS

  • American Board of Pediatrics, Pediatric Hematology and Oncology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 08 01; 19(8):945-977. View abstract
  2. Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor. J Natl Compr Canc Netw. 2021 08 01; 19(8):978-985. View abstract
  3. Haplotype-resolved germline and somatic alterations in renal medullary carcinomas. Genome Med. 2021 Jul 14; 13(1):114. View abstract
  4. Author Correction: PGBD5 promotes site-specific oncogenic mutations in human tumors. Nat Genet. 2020 Nov; 52(11):1265. View abstract
  5. Phase I/II Study of Stereotactic Body Radiation Therapy for Pulmonary Metastases in Pediatric Patients. Adv Radiat Oncol. 2020 Nov-Dec; 5(6):1267-1273. View abstract
  6. A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group AREN0321 study. Cancer. 2020 12 01; 126(23):5156-5164. View abstract
  7. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559. View abstract
  8. Results of Treatment for Patients With Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor (AREN0534): A report from the Children's Oncology Group. Cancer. 2020 08 01; 126(15):3516-3525. View abstract
  9. DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020 10; 33(10):1910-1921. View abstract
  10. Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children's Oncology Group study AREN03B2. Cancer. 2020 06 15; 126(12):2866-2871. View abstract
  11. Imaging Characteristics of Nephrogenic Rests Versus Small Wilms Tumors: A Report From the Children's Oncology Group Study AREN03B2. AJR Am J Roentgenol. 2020 05; 214(5):987-994. View abstract
  12. Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study. J Clin Oncol. 2020 05 10; 38(14):1558-1568. View abstract
  13. Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. Clin Cancer Res. 2020 06 15; 26(12):2882-2890. View abstract
  14. 50 Years Ago in TheJournal ofPediatrics: 50 years of progress in renal cell carcinoma: From case reports to targeted therapy. J Pediatr. 2020 03; 218:120. View abstract
  15. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report. J Clin Oncol. 2019 10 20; 37(30):2769-2777. View abstract
  16. Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilms' tumor. JCI Insight. 2019 08 08; 4(15). View abstract
  17. Treatment of stage I anaplastic Wilms' tumour: a report from the Children's Oncology Group AREN0321 study. Eur J Cancer. 2019 09; 118:58-66. View abstract
  18. Reply to L. Xie et al. J Clin Oncol. 2019 05 10; 37(14):1264-1265. View abstract
  19. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8. View abstract
  20. Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. J Clin Oncol. 2018 Oct 18; JCO1800076. View abstract
  21. Reply to D.M. Green. J Clin Oncol. 2018 Sep 13; JCO1800659. View abstract
  22. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer. 2019 02; 17(1):1-6. View abstract
  23. Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. JCO Precis Oncol. 2018; 2018. View abstract
  24. The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing. Cancer. 2018 08; 124(16):3381-3389. View abstract
  25. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol. 2018 06 01; 36(16):1564-1570. View abstract
  26. Reply to B. Zhang et al. J Clin Oncol. 2018 05 10; 36(14):1454-1455. View abstract
  27. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. J Clin Oncol. 2018 01 20; 36(3):254-261. View abstract
  28. Erratum: PGBD5 promotes site-specific oncogenic mutations in human tumors. Nat Genet. 2017 09 27; 49(10):1558. View abstract
  29. Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group. Ann Surg. 2017 09; 266(3):470-478. View abstract
  30. Imaging of renal medullary carcinoma in children and young adults: a report from the Children's Oncology Group. Pediatr Radiol. 2017 Nov; 47(12):1615-1621. View abstract
  31. Renal Medullary Carcinoma: Establishing Standards in Practice. J Oncol Pract. 2017 07; 13(7):414-421. View abstract
  32. PGBD5 promotes site-specific oncogenic mutations in human tumors. Nat Genet. 2017 Jul; 49(7):1005-1014. View abstract
  33. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532. Ann Surg. 2017 04; 265(4):835-840. View abstract
  34. Synchronous occurrence of acute lymphoblastic leukemia and wilms tumor in two patients: underlying etiology and combined treatment plan. Pediatr Blood Cancer. 2017 05; 64(5). View abstract
  35. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. J Clin Oncol. 2016 09 10; 34(26):3189-94. View abstract
  36. Surgical protocol violations in children with renal tumors provides an opportunity to improve pediatric cancer care: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2016 11; 63(11):1905-10. View abstract
  37. Pediatric cystic nephromas: distinctive features and frequent DICER1 mutations. Hum Pathol. 2016 Feb; 48:81-7. View abstract
  38. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. J Clin Oncol. 2015 Sep 20; 33(27):2999-3007. View abstract
  39. Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2. Cancer. 2015 Jul 15; 121(14):2457-64. View abstract
  40. Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children's Oncology Group. Pediatr Radiol. 2015 Feb; 45(2):166-72. View abstract
  41. Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: implications for central venous catheter placement. J Pediatr Urol. 2014 Oct; 10(5):969-73. View abstract
  42. DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. Mod Pathol. 2014 Sep; 27(9):1267-80. View abstract
  43. Inter-rater reliability of surgical reviews for AREN03B2: a COG renal tumor committee study. J Pediatr Surg. 2014 Jan; 49(1):154-8; discussion 158. View abstract
  44. Uncle Sam and your job options. Considering your next career move? Consider the tax implications. Del Med J. 2013 May; 85(5):147-9. View abstract
  45. Primary nephrectomy and intraoperative tumor spill: report from the Children's Oncology Group (COG) renal tumors committee. J Pediatr Surg. 2013 Jan; 48(1):34-8. View abstract
  46. Children's Oncology Group's 2013 blueprint for research: renal tumors. Pediatr Blood Cancer. 2013 Jun; 60(6):994-1000. View abstract
  47. Detection of preoperative wilms tumor rupture with CT: a report from the Children's Oncology Group. Radiology. 2013 Feb; 266(2):610-7. View abstract
  48. Barriers to the enrollment of children in the Children's Oncology Group study of very low risk Wilms tumor: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2011 Oct; 33(7):521-3. View abstract
  49. The impact of surveillance imaging on overall survival in patients with recurrent Wilms tumor: A report from the Children's Oncology Group. J Clin Oncol. 2011 May 20; 29(15_suppl):9536. View abstract
  50. Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study. J Clin Oncol. 2007 Jul 20; 25(21):3130-6. View abstract
  51. Pediatric Oncologic Emergencies. Nathan & Oski's Hematology Textbook of Infancy and Childhood. 2007; In Press. View abstract
  52. The effects of postoperative pain and its management on postoperative cognitive dysfunction. Am J Geriatr Psychiatry. 2007 Jan; 15(1):50-9. View abstract
  53. Universal session-level change processes in an early session of psychotherapy: path models. J Consult Clin Psychol. 2006 Apr; 74(2):327-36. View abstract
  54. Section Editor, Oncology. Pediatric Hospitalist Textbook, Chiang. 2006. View abstract
  55. Oncologic Emergencies Chapter. Pediatric Hospitalist Textbook, Chiang. 2006. View abstract
  56. Postoperative delirium: the importance of pain and pain management. Anesth Analg. 2006 Apr; 102(4):1267-73. View abstract
  57. Exploring the psychological underpinnings of the moral mandate effect: motivated reasoning, group differentiation, or anger? J Pers Soc Psychol. 2006 Apr; 90(4):629-43. View abstract
  58. Section Editor, Oncology. Pediatric Hospitalist Textbook. 2006. View abstract
  59. The Safety of Oral Magnesium Pidolate in Children with Hemoglobin SC Disease. Presented at the 28th Annual Meeting of the National Sickle Cell Disease Program. 2005. View abstract
  60. Multiple micronutrient deficiencies in a child fed an elemental formula. J Pediatr Gastroenterol Nutr. 2001 Nov; 33(5):602-5. View abstract
  61. Clinical Practice Guidelines for the treatment of patients with Sickle Cell Disease, on the topic of Acute Chest. 2001. View abstract
  62. Clinical Practice Guidelines on the treatment of patients with Sickle Cell Disease, on the topic of Transfusion. 2001. View abstract
  63. Multiple Micronutrient Deficiencies in a Child Fed an Elemental Formula. Journal of Pediatric Oncology. 2001; (5):602-605. View abstract
  64. Clinical Practice Guidelines for the treatment of patients with Sickle Cell Disease, on the topic of Pain. 2000. View abstract
  65. Clinical Practice Guidelines for the treatment of patients with Sickle Cell Disease, on the topic of Routine Health Maintainence and Priapism. 2000. View abstract
  66. Clinical Practice Guidelines for the treatment of patients with Sickle Cell Disease, on the topic of Fever. 2000. View abstract
  67. Clinical Practice Guidelines for the treatment of patients with Sickle Cell Disease, on the topic of Splenic Sequestration. 2000. View abstract
  68. Clinical Practice Guidelines for the treatment of Pain in Sickle Cell Disease. 2000. View abstract
  69. Clinical Practice Guidelines for the treatment of Fever in Sickle Cell Disease. 2000. View abstract
  70. Clinical Practice Guidelines for the treatment of Fever and Neutropenia. 2000. View abstract
  71. Multiple Mechanisms of Cell Injury in the Gastric Mucosa. Federal Proceedings. 1991; 46:1152. View abstract
  72. Biochemical Characterization of a Boving Corneal Angiogenesis Inhibitor. 1991. View abstract
  73. Fluorogenic Assay of Proteinase Activity in Developing Rat Enamel. Journal of Dental Research. 1989; 68:239. View abstract
  74. Abundant Occurrence of Gamma-Carboxyglutamic Acid-Containing Peptides in the Gastropod Family. Current Advances in Vitamin K Research. Ed. John Suttie. 1988. View abstract
  75. An examination of the Vitamin K Cycle: Phenytoin Interference in K-dependent Carboxylase Activity. 1985. View abstract